Antwerp, Belgium, November 17, 2025. Agomab Therapeutics NV (‘Agomab’) today announced positive data from 103 participants completing 12 weeks of treatment in the STENOVA Phase 2a clinical trial for ontunisertib (AGMB-129), an investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGFβ RI or ALK5) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).

Antwerp, Belgium, April 10, 2025 – Agomab Therapeutics NV (‘Agomab’) today announced that interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGFβ-RI or ALK5) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD), will be presented as a late-breaking presentation at Digestive

— AGMB-129 hit all primary and secondary endpoints in interim read-out from 44 patients after 12 weeks treatment — Detailed interim STENOVA results to be presented at future scientific conference — STENOVA clinical trial on track to report full results in the fourth quarter of 2025 — Open-label extension study initiated